Journal of Antimicrobial Chemotherapy (2000) 46, 725-732
© 2000 The British Society for Antimicrobial Chemotherapy
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses
a Department of Pharmacokinetics, Centre for Science and Technology LekBioTech, 8 Nauchny proezd, Moscow 117246, Russia; b Department of Medicine, Mount Auburn Hospital, Cambridge, MA, USA
To demonstrate the impact of the different pharmacokinetics of moxifloxacin and levofloxacin on their antimicrobial effects (AMEs), killing and regrowth kinetics of two clinical isolates of Staphylococcus aureus and one each of Escherichia coli and Klebsiella pneumoniae were studied. With each organism, a series of monoexponential pharmacokinetic profiles of single doses of moxifloxacin (T1/2 = 12.1 h) and levofloxacin (T1/2 = 6.8 h) were simulated. The respective eight-fold ranges of the ratios of area under the concentration–time curve (AUC) to the MIC were 58–475 and 114–934. Species- and strain-independent linear relationships observed between the intensity of AME (IE) and log AUC/MIC were not superimposed for moxifloxacin and levofloxacin (r2 = 0.99 in both cases). The predicted AUC/MIC ratios for moxifloxacin and levofloxacin that might be equivalent to Schentag's AUC/MIC breakpoint for ciprofloxacin (125) were estimated at 80 and 130, respectively. The respective equivalent MIC breakpoints were 0.41 mg/L (for a 400 mg dose of moxifloxacin) and 0.35 mg/L (for a 500 mg dose of levofloxacin). Based on the IE–log AUC/MIC relationships, equiefficient 24 h doses (D24s) of moxifloxacin and levofloxacin were calculated for hypothetical strains of S. aureus, E. coli and K. pneumoniae with MICs equal to the respective MIC50s (weighted geometric means of reported values). To provide an ‘acceptable’ IE = 200 (log cfu/mL)•h, the D24s of moxifloxacin for all three organisms were much lower (150, 30 and 60 mg, respectively) than the clinically proposed 400 mg dose. Although the usual dose of levofloxacin (500 mg) would be in excess for E. coli and K. pneumoniae (D24 = 36 and 220 mg, respectively), it might be insufficient for S. aureus (the estimated D24 = 850 mg). Moreover, to provide the same effect as a 400 mg D24 of moxifloxacin against staphylococci, levofloxacin would have to be given in a 5000 mg D24, which is 10-fold higher than its clinically accepted dose. The described method of generalization of data obtained with specific organisms to other representatives of the same species might be useful to predict the AMEs of new quinolones.
1 Corresponding author. Tel: +7-095-332-3435; Fax: +7-095-332-3335; E-mail: firsov{at}dol.ru
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Singh, K. R. Ledesma, K.-T. Chang, J.-G. Hou, R. A. Prince, and V. H. Tam Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model J. Antimicrob. Chemother., September 1, 2009; 64(3): 556 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Firsov, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. N. Vostrov, I. Yu. Lubenko, A. P. Arzamastsev, Y. A. Portnoy, and S. H. Zinner ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model J. Antimicrob. Chemother., July 1, 2004; 54(1): 178 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Croisier, M. Etienne, E. Bergoin, P.-E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1699 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Joukhadar, H. Stass, U. Muller-Zellenberg, E. Lackner, F. Kovar, E. Minar, and M. Muller Penetration of Moxifloxacin into Healthy and Inflamed Subcutaneous Adipose Tissues in Humans Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3099 - 3103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J Schentag, A. K Meagher, and A. Forrest Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: Part 1: In Vitro and Animal Models Ann. Pharmacother., September 1, 2003; 37(9): 1287 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. N. Vostrov, I. Y. Lubenko, K. Drlica, Y. A. Portnoy, and S. H. Zinner In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1604 - 1613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Firsov, S. H. Zinner, S. N. Vostrov, Y. A. Portnoy, and I. Yu. Lubenko AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin J. Antimicrob. Chemother., October 1, 2002; 50(4): 533 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. MacKenzie, K. E. Milne, and I. M. Gould Calculation of composite recovery time: a new pharmacodynamic parameter J. Antimicrob. Chemother., August 1, 2002; 50(2): 281 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Zinner, A. A. Firsov, D. Gilbert, K. Simmons, and I. Yu. Lubenko The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses J. Antimicrob. Chemother., December 1, 2001; 48(6): 821 - 826. [Abstract] [Full Text] [PDF]
|
|